CA-ARMIS
Armis, the asset intelligence cybersecurity company, today announced that it has been named a Top Performer in the 2024 Best in KLAS Software & Services Report for Healthcare IoT Security for the second year in a row. The Best in KLAS report recognizes software and services companies that excel in helping healthcare professionals improve patient care.
“This recognition from KLAS which is based solely on customer reviews is a true testament to our ongoing commitment to protecting the attack surfaces of healthcare organizations,” said Mohammad Waqas, CTO of Healthcare at Armis. “I want to thank every Armis customer who took the time this year to share with KLAS their experience with Armis CentrixTM for Medical Device Security. Your feedback is instrumental in helping us continuously improve our solutions and deliver the best possible value to the healthcare community.”
The 2024 Best in KLAS report, based on independent feedback from healthcare providers in North America, evaluates vendors across six key performance areas: culture, loyalty, operations, product, relationship and value. Armis achieved an outstanding overall score, demonstrating excellence in every category and solidifying the company’s position as a leader in Healthcare IoT Security.
When asked about Armis, customers shared the following anonymized comments with KLAS in review of the company’s solution:
- “Given the nature of how sensitive and aware we have all become to some of the hazards surrounding cybersecurity and cyber risks associated with penetration into personal health information through many different avenues of medical devices and applications, the Armis application is robust in being able to see all network-connected devices. It is really incredible to see the amount of horsepower that the Armis platform brings to the table for us. The product really is a great tool. Not only can the reporting piece identify connected devices but it is able to identify what type of device something is through the product's algorithms. The product is able to determine what the make, model, and serial number are, and in some cases, what operating system the device is functioning on. Recently, we had an issue with updating the security on anything that was still running on something other than Windows 10, and through the Armis system, we were able to see how many devices were reporting through the application that were not up to Windows 10. With the reporting structure, we now have a line of sight into many things we didn't know about.” - Director, April 2023
- “Armis does very well with implementations. They are very knowledgeable about their products. They have experts on their team, so if we need some help with a configuration, they have resources available that are on standby typically to help and engage in troubleshooting.” - Analyst/Coordinator, April 2023
- “In general, Armis regularly updates their platform and gives good notifications about new enhancements and new features. They back those notifications up with written material and videos, as well as live sessions if we are lucky enough to find the time to attend them. It is good that the vendor is constantly adding new features and new capabilities to the product.” - Analyst/Coordinator, September 2023
In July 2023, Armis was rated the best-performing cross-industry vendor in the KLAS Healthcare IoT Security 2023 report for its deep coverage of IoT, OT, IoMT and IT across all verticals.
In the past year, Armis has continued to deepen its commitment to securing healthcare organizations. Combining the power of Armis CentrixTM, the cyber exposure management platform, and the Armis AI-powered Asset Intelligence Engine, Armis has reinforced its healthcare-specific capabilities which help to provide complete visibility and security for all medical devices, clinical assets and the entire healthcare ecosystem with zero disruptions to patient care.
Armis is a sponsor of HIMSS 2024, taking place in Orlando, FL March 11-15. Stop by Armis’ booth #1621 in the CyberSecurity Command Center or visit the team in the Main Walkway at booth #1048. At HIMSS, Armis’ CTO of Healthcare, Mohammad Waqas, will speak to “Building a Comprehensive Healthcare Security Program for Next-Gen Patient Care.” This session will be held on Tuesday, March 12th from 10:15am - 10:30am EDT in the Orange County Convention Center, Theatre A.
To read the KLAS report, please visit: 2024 Best in KLAS - Software & Services
To learn more about Armis CentrixTM for Medical Device Security, go to: https://www.armis.com/platform/armis-centrix-for-medical-device-security/
About Armis
Armis, the asset intelligence cybersecurity company, protects the entire attack surface and manages the organization's cyber risk exposure in real time. In a rapidly evolving, perimeter-less world Armis ensures that organizations continuously see, protect and manage all critical assets. Armis secures Fortune 100, 200 and 500 companies as well as national governments, state and local entities to help keep critical infrastructure, economies and society stay safe and secure 24/7. Armis is a privately held company headquartered in California.
About KLAS Research
KLAS is a research and insights firm on a global mission to improve healthcare. Working with thousands of healthcare professionals and clinicians, KLAS gathers data and insights on software and services to deliver timely reports and performance data that represent provider and payer voices and act as catalysts for improving vendor performance. The KLAS research team publishes reports covering the most pressing questions facing healthcare technology today, including emerging technology insights, that provide early insights on the future of healthcare technology solutions. KLAS also fosters measurement and collaboration between healthcare providers and payers and best practice adoption. Learn more at klasresearch.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240212843101/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom